#1 Clinical Trials Search in Europe

Recombinant Interferon Beta-1B

This article explores recent clinical trials investigating the use of Recombinant Interferon Beta-1B in treating multiple sclerosis (MS). These studies aim to evaluate the drug’s effectiveness, safety, and potential benefits for patients with various forms of MS, including relapsing-remitting and progressive types. The trials compare Recombinant Interferon Beta-1B to other treatments and examine its role in disease management strategies for different patient populations.

Table of Contents

What is Recombinant Interferon Beta-1B?

Recombinant interferon beta-1b is a medication used to treat multiple sclerosis (MS). It is a man-made version of a protein called interferon beta that occurs naturally in the human body[1]. This medication is sold under the brand names Betaferon and Extavia.

Interferon beta-1b belongs to a class of drugs called disease-modifying therapies (DMTs) for MS. These medications aim to reduce the frequency and severity of MS relapses and slow the progression of disability.

How Does it Work?

While the exact mechanism is not fully understood, interferon beta-1b is believed to work by:

  • Reducing inflammation in the central nervous system
  • Preventing the immune system from attacking the protective covering of nerves (myelin)
  • Potentially promoting repair of damaged myelin

By modulating the immune response, interferon beta-1b helps to reduce the damage caused by MS to the brain and spinal cord[2].

What is it Used For?

Recombinant interferon beta-1b is primarily used to treat relapsing forms of multiple sclerosis, including:

  • Relapsing-remitting MS (RRMS): The most common form of MS, characterized by clearly defined attacks of worsening neurologic function followed by periods of partial or complete recovery
  • Secondary progressive MS (SPMS): A form that follows RRMS, where disability progressively worsens with or without relapses
  • Clinically isolated syndrome (CIS): A first episode of neurologic symptoms lasting at least 24 hours, caused by inflammation or demyelination in the central nervous system

It is typically prescribed for patients who have experienced at least two relapses within the last two years[1].

How is it Administered?

Interferon beta-1b is administered as a subcutaneous (under the skin) injection. The typical dosing schedule is:

  • 250 micrograms (0.25 mg) every other day
  • The medication comes as a powder that needs to be mixed with a provided solvent before injection
  • Patients or caregivers can be trained to administer the injections at home

It’s important to rotate injection sites to minimize skin reactions and discomfort[3].

How Effective is it?

Clinical trials have shown that interferon beta-1b can:

  • Reduce the frequency of MS relapses by about 30%
  • Decrease the severity of relapses
  • Slow the progression of disability
  • Reduce the number of new brain lesions seen on MRI scans

However, it’s important to note that the medication does not cure MS and its effectiveness can vary between individuals[2].

What are the Potential Side Effects?

Common side effects of interferon beta-1b include:

  • Flu-like symptoms (fever, chills, muscle aches) after injections
  • Injection site reactions (redness, pain, swelling)
  • Headache
  • Fatigue
  • Weakness

Less common but more serious side effects can include liver problems, depression, and allergic reactions. Patients should report any unusual symptoms to their healthcare provider[3].

Important Considerations

When considering or using interferon beta-1b, patients should keep in mind:

  • Regular blood tests are needed to monitor liver function and blood cell counts
  • The medication may not be suitable for patients with certain liver conditions, severe depression, or specific heart problems
  • It may take several months to see the full benefits of the treatment
  • Pregnancy and breastfeeding considerations should be discussed with a healthcare provider
  • The long-term safety and efficacy of interferon beta-1b (beyond 25 months) is still being studied[1][3]

As with any medication, the decision to use interferon beta-1b should be made in consultation with a healthcare provider, considering the individual patient’s condition, medical history, and personal preferences.

Aspect Details
Drug Name Recombinant Interferon Beta-1B
Administration Subcutaneous injection
Dosage Typically 250 micrograms every other day
MS Types Studied Relapsing-Remitting MS, Progressive MS
Main Objectives Evaluate efficacy in slowing disease progression, reducing relapses, improving quality of life
Key Outcome Measures EDSS, T25FW, 9-HPT, SDMT, MRI metrics (brain volume, lesions)
Safety Assessments Adverse events, tolerability, laboratory abnormalities
Comparison Treatments Placebo, other disease-modifying therapies (DMTs)
Trial Durations Ranging from 96 weeks to 2 years

FAQ

  • What is Recombinant Interferon Beta-1B? Recombinant Interferon Beta-1B is a medication used to treat multiple sclerosis. It's a lab-made version of a protein that occurs naturally in the body and helps regulate the immune system.
  • How is Recombinant Interferon Beta-1B administered? Recombinant Interferon Beta-1B is typically administered through subcutaneous injection, which means it's injected just under the skin.
  • What types of multiple sclerosis are being studied with this drug? The clinical trials are studying various types of multiple sclerosis, including relapsing-remitting MS (RRMS) and progressive forms of MS.
  • What are some of the main goals of these clinical trials? The main goals include evaluating the drug's effectiveness in slowing disease progression, reducing relapses, improving quality of life, and assessing its safety and tolerability compared to other treatments.
  • How long do these clinical trials typically last? The duration of these trials varies, but they often last for several months to a few years. For example, one study mentioned lasts for 96 weeks (about 2 years).

Ongoing Clinical Trials on Recombinant Interferon Beta-1B

  • Study on Stopping Dimethyl Fumarate and Drug Combination in Patients Aged 55+ with Inactive Relapsing-Remitting Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study on Metformin for Delaying Progression in Non-Active Progressive Multiple Sclerosis Patients

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Multiple Sclerosis (MS): A chronic disease affecting the central nervous system, where the immune system attacks the protective covering of nerves.
  • Relapsing-Remitting MS (RRMS): A type of MS characterized by clearly defined attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
  • Progressive MS: A form of MS where neurologic function worsens steadily over time, with or without periods of relapse and remission.
  • EDSS (Expanded Disability Status Scale): A method of measuring disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • T25FW (Timed 25-Foot Walk): A test that measures walking speed and is used to assess leg function and mobility in MS patients.
  • 9-HPT (Nine-Hole Peg Test): A test that measures finger dexterity and is used to assess arm and hand function in MS patients.
  • SDMT (Symbol Digit Modalities Test): A cognitive test that measures processing speed and is used to assess cognitive function in MS patients.
  • MRI (Magnetic Resonance Imaging): A medical imaging technique used to produce detailed images of the brain and spinal cord, helping to diagnose and monitor MS.
  • Gd+ T1 lesion: An area of active inflammation in the brain or spinal cord that can be seen on an MRI scan after the injection of a contrast agent called gadolinium.
  • T2 lesion: An area of damage in the brain or spinal cord that can be seen on an MRI scan, representing the total burden of disease in MS.

References

  1. http://clinicaltrials.eu/trial/study-on-stopping-dimethyl-fumarate-and-drug-combination-in-patients-aged-55-with-inactive-relapsing-remitting-multiple-sclerosis/
  2. http://clinicaltrials.eu/trial/study-on-metformin-for-delaying-progression-in-non-active-progressive-multiple-sclerosis-patients/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-tolerability-of-ofatumumab-compared-to-a-drug-combination-for-patients-with-newly-diagnosed-relapsing-multiple-sclerosis/